AVITA Medical (AVITA Medical) 3-Year EBITDA Growth Rate : 13.50% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical 3-Year EBITDA Growth Rate?

AVITA Medical's EBITDA per Share for the three months ended in Dec. 2023 was $-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 13.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 6.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of AVITA Medical was 81.60% per year. The lowest was -243.80% per year. And the median was 5.50% per year.

Competitive Comparison of AVITA Medical's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, AVITA Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where AVITA Medical's 3-Year EBITDA Growth Rate falls into.

AVITA Medical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

AVITA Medical (OTCPK:AVHHL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

AVITA Medical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of AVITA Medical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (AVITA Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

RCEL:USA 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.